Xopenex

Levosalbutamol

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xopenex

What is Xopenex?

Xopenex is a brand-name prescription medication that contains the active ingredient levalbuterol. It belongs to a class of drugs known as short-acting beta-agonists (SABAs), which are commonly referred to as bronchodilators.

Mechanism of Action

The medication works by targeting the smooth muscle tissues that surround the airways in the lungs. By stimulating specific receptors, it encourages these muscles to relax. When the muscles relax, the bronchial tubes widen, allowing for increased airflow and making it easier to breathe.

Primary Uses

Xopenex is primarily utilized to manage and prevent bronchospasm, a condition characterized by the sudden tightening of the muscles in the airway walls. It is frequently prescribed for individuals with obstructive airway diseases, including:

Asthma: A chronic condition where airways become narrow, swollen, and produce extra mucus.
Chronic Obstructive Pulmonary Disease (COPD): A group of progressive lung diseases, including emphysema and chronic bronchitis, that cause airflow blockage and breathing-related problems.

Comparison to Albuterol

While Xopenex is chemically related to albuterol, it is a single-isomer formulation. Conventional albuterol consists of a mixture of two isomers (R-albuterol and S-albuterol). Xopenex contains only the R-isomer, which is the component responsible for the relaxation of the airway muscles.

What side effects are possible with Xopenex?

Possible Side Effects and Safety Information

The official safety documentation for Xopenex (Levosalbutamol) establishes its adverse reaction profile based on its function as a Short-Acting Beta-Agonist (SABA). Adverse reactions are categorized by frequency and the body system affected, reflecting data derived from clinical trials and post-marketing surveillance, consistent with regulatory standards.

Frequency-Classified and Systemic Effects

Adverse reactions classified as Common in regulatory documents often reflect systemic stimulation due to the drug's activity, primarily including effects on the heart and nervous system. The most frequently reported effects include headache, tachycardia (increased heart rate), tremor, nervousness, and dizziness. Effects are classified into major system-organ classes, such as Cardiac Disorders and Nervous System Disorders.

Serious Adverse Reactions and Restrictions

Regulatory labeling specifies clinically significant, less frequent reactions that warrant attention. A critical safety concern documented in warnings is paradoxical bronchospasm, an immediate, acute worsening of breathing that occurs immediately following administration. Other serious reactions include severe hypersensitivity reactions (e.g., angioedema, urticaria) and the potential for clinically significant cardiovascular effects, such as serious arrhythmias.

Safety constraints necessitate caution in certain populations. Due to its systemic effects, the medication requires careful consideration in individuals with pre-existing conditions like cardiovascular disorders (including hypertension or coronary insufficiency), hyperthyroidism, or diabetes mellitus. The potential for drug-induced hypokalemia (low potassium levels) is also a documented safety element.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Xopenex (Levosalbutamol) is a medical emergency primarily characterized by an extreme exaggeration of the drug's intended effects, known as beta-adrenergic stimulation. Regulatory documents warn that fatalities have been reported in association with the excessive use of inhaled sympathomimetic agents.

Documented Manifestations and Severe Outcomes

Official labeling defines overdose manifestations that require immediate attention. These primarily affect the cardiovascular and metabolic systems:

Cardiovascular: Severe tachycardia (rapid heart rate), cardiac arrhythmias (irregular heartbeats), and chest pain or tightness. In severe cases, the risk includes cardiac arrest and seizures.
Metabolic/Physiological: Documented abnormalities include acute hypokalemia (low potassium) and hyperglycemia (high blood sugar). ECG changes (e.g., QTc prolongation) are also noted.

Required Emergency Actions

The most important action mandated by regulatory authorities is to seek immediate medical attention for all suspected overdose situations. This is necessary because of the potential for life-threatening systemic events. Management for overdose is officially described as symptomatic and supportive treatment in a medical setting, which includes continuous monitoring of ECG, serum potassium, and blood glucose levels. No specific antidote is documented in the official prescribing information.

Therapeutic Uses of Xopenex

What Xopenex Treats: Main Uses and Benefits

Xopenex (Levosalbutamol) is commonly used to help provide supportive symptomatic relief during episodes of acute breathing difficulty stemming from narrowed airways. It is considered relevant in contexts where short-term symptomatic assistance is needed, assisting the patient with improved respiration.

Support for Bronchospasm and Airway Tightness

This therapeutic domain is relevant for the sudden tightening of the muscles around the airways (bronchospasm), which is the core focus of symptomatic support. It is indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is commonly applied in conditions like asthma and Chronic Obstructive Pulmonary Disease (COPD), including associated chronic bronchitis and emphysema.

“The quick-relief classification of this medication means its use is centered on responding to acute symptomatic episodes rather than providing daily, long-term disease control.”

The practical benefit is supportive relief that helps ease the feeling of chest tightness and assists with the symptomatic discomfort of the physical distress cluster, which supports improved comfort. It is used to help address pronounced symptoms of respiratory distress, such as acute wheezing, sudden shortness of breath (dyspnea), and persistent coughing.

Quick Fact: Relief for Acute Symptoms
This medication is primarily used as as-needed reliever therapy for acute manifestations of wheezing and shortness of breath when they interfere with daily functioning.

Symptomatic Support Across Patient Groups

The drug is relevant for addressing bronchospasm across key populations, including adults, adolescents, and children aged 4 years and older, provided they have a reversible obstructive airway disease. This application is relevant in clinical settings where supportive symptomatic management is appropriate for patients across these age ranges.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Xopenex

Eligibility Scope	Official Regulatory Status
Populations for whom use is allowed	Adults, adolescents, and children with reversible obstructive airway disease.
Populations for whom use is contraindicated	Patients with a known history of hypersensitivity to Levosalbutamol, racemic albuterol, or any component of the product.
Age-related eligibility rules	Established use begins at age 4 years (Inhalation Aerosol) or 6 years (Inhalation Solution). Safety and efficacy are not established below these respective ages.
Condition-specific eligibility rules	Use requires caution in patients with certain cardiovascular disorders (e.g., coronary insufficiency, hypertension, cardiac arrhythmias), diabetes mellitus, hyperthyroidism, or convulsive disorders.
Pregnancy and lactation eligibility	Pregnancy: Use is categorized by the Risk Summary framework; the benefit must justify the potential risk to the fetus. Lactation: It is unknown if the drug is excreted in human milk; caution is required.

Official eligibility statements:

Regulatory documents define that Xopenex is contraindicated for any patient with a history of allergy to the drug or racemic albuterol. Eligibility for use is established only in patients who meet the specific age minimums for the given formulation. Additionally, the drug must be used with caution in patients having pre-existing conditions such as certain cardiac, metabolic, or convulsive disorders, reflecting a restricted patient population.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Xopenex (Levosalbutamol) defines specific drug-drug interactions based on pharmacodynamic conflicts, additive effects, and one documented exposure alteration. Timing-based constraints are not specified in the labeling, and no specific food, alcohol, or herbal product interactions are officially documented.

Pharmacodynamic Antagonism and Potentiation

Co-administration with beta-adrenergic blocking agents may lead to the antagonism of Levosalbutamol's bronchodilatory effects, carrying the documented risk of inducing severe bronchospasm. Official prescribing information states that patients with asthma should not normally be treated with beta-blockers.

Additive sympathomimetic effects are documented with Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), and other adrenergic drugs. These combinations may potentiate the effect of Levosalbutamol on the cardiovascular system, increasing the potential for serious adverse cardiac events.

Interactions involving non-potassium-sparing diuretics (such as thiazides or loop diuretics) carry an additive risk of worsening hypokalemia or electrocardiographic changes.

Exposure Modification and Clearance

Use of Levosalbutamol has been documented to decrease the serum concentrations of co-administered Digoxin. A specific population-based caution is noted for patients with renal impairment, as the effects of high doses may be increased due to the slower rate of drug removal from the body, as recognized in official labeling.

Mechanism of Action

The mechanism of Levosalbutamol is centered on the highly specific activation (agonism) of the beta2-adrenergic receptors (beta2ARs) located in the airways. By directly engaging these receptors, which are primarily found on the bronchial smooth muscle, the drug initiates a signal that influences muscle contraction dynamics. This receptor activation is the critical first step that leads to the physical relaxation of the airway muscles (bronchodilation), which is the resultant physiological consequence of the drug's action.

Following receptor activation, Levosalbutamol triggers an intracellular cascade involving the increase of the signaling molecule cyclic AMP (cAMP). The resulting high cAMP levels modulate key enzymes, such as Myosin Light Chain Kinase (MLCK), effectively inhibiting the cell's ability to contract. This deep interference with the biochemical machinery of contraction promotes the widening of the bronchial tubes, which constitutes the final physiological effect of the mechanism. The drug's specificity is derived from its pure R-enantiomer composition. However, this mechanism is subject to a limitation known as receptor desensitization (tachyphylaxis), where the beta2ARs can become less responsive with excessive use, resulting in a reduction of the beta2AR-mediated physiological response over time.

Dosage and Administration Information

How to Use Xopenex

The administration of Xopenex (Levosalbutamol) is strictly limited to the Oral Inhalation route, ensuring the medication is delivered directly to the respiratory system. The medication is supplied either as an Inhalation Solution for use with a standard jet nebulizer or as an Inhalation Aerosol (Metered-Dose Inhaler or MDI).

Standard Dosing and Frequency

For adults and adolescents aged 12 years and older, the Inhalation Solution typically begins at a dose of 0.63 mg, administered three times a day (TID). This regimen is intended to maintain intervals of approximately six to eight hours between doses, and the dosage may be adjusted upward to a maximum of 1.25 mg. The Inhalation Aerosol is generally administered as two inhalations (90 mcg) every four to six hours, as directed.

Administration Rules for Specific Groups

Specific dosing applies to pediatric patients. Children aged 6 to 11 years use a lower recommended dose of 0.31 mg of the nebulizer solution TID, which should not routinely exceed 0.63 mg. The Inhalation Solution is not approved for children under 6 years of age. For MDI use, the adult regimen applies to children aged 4 years and older. Caution is advised for high doses of the nebulized solution in patients with renal impairment.

Preparation and Handling

The 1.25 mg solution concentrate requires dilution with sterile normal saline prior to nebulization. The Inhalation Aerosol device must be primed with four test sprays before initial use or if unused for more than three days. It is a critical instruction that the total dose or frequency must not be exceeded.

Recent Clinical Evidence

Research evidence / Overview of studies for Xopenex (Levosalbutamol)

Evidence for use in Bronchospasm (Adults and Adolescents)

Levosalbutamol was evaluated in short-term randomized controlled trials (RCTs) evaluating outcomes related to acute respiratory symptoms in adults and adolescents. These studies were used in research exploring how lung function changes over time, specifically measuring the Forced Expiratory Volume in 1 second (FEV1), which is a functional measure of how much air a person can exhale in one second. Research also examined subjective outcomes related to physical discomfort, such as patient-reported breathing difficulties.

These trials were designed as double-blind studies. Findings describe patterns observed in the studies, where researchers reported measurements of FEV1 across both the Levosalbutamol and placebo groups. The evidence contributes to understanding symptom patterns and acute changes in lung function over defined time intervals.

Evidence for use in Bronchospasm (Children)

Research specifically examined Levosalbutamol in the pediatric population, primarily focusing on children aged 4 to 11 years who have conditions characterized by fluctuating or episodic manifestations, such as asthma. Outcomes monitored included changes in FEV1 and patient-reported outcomes describing perceived discomfort and symptom intensity.

The findings for children aged 4 and older described patterns that were similar to those observed in adults and adolescents. Specialized research was also required to examine the effect in infants and young children (under age 4). Data for this youngest group remain insufficient, as researchers observed varied outcomes and did not consistently establish the same measurements of effect seen in older children across all study endpoints.

Comparative Evidence: Studies vs. Racemic Albuterol

Studies explored differences in objective functional measures, such as FEV1, and patient-reported experiences related to physical discomfort when comparing Levosalbutamol and racemic albuterol. Systematic reviews indicate that while Levosalbutamol was observed in some studies to have distinct patterns regarding lung function, comparative evidence is lacking for a substantial difference in overall, long-term clinical outcomes (like hospitalization or symptom control) when measured against racemic albuterol. Findings were mixed across studies, suggesting that the clinical advantage over the older mixture is not fully established, particularly for long-term use.

Long-Term Research and Evidence Gaps

The current body of research provides context but not individual predictions regarding long-term use. The evidence is largely based on short- to intermediate-term follow-up durations, meaning the long-term effects are not fully established. Research has focused extensively on acute response and short-term symptom patterns, but there is limited information for long-term outcomes or the durability of effect beyond the initial study periods. The evidence quality is characterized as High for the acute functional changes observed (over hours), but certainty remains low for outcomes over many months or years of use, and these limitations remain recognized research gaps.

Key Studies & References Levalbuterol versus albuterol for acute asthma: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Xopenex (FAQ)

Q: Can Xopenex be used during pregnancy or while breastfeeding?

A: Regulatory documents address use during pregnancy using a Risk Summary framework, which means the potential benefit must justify the potential risk to the fetus. Regarding lactation, it is unknown whether the drug is excreted into human milk, and caution is required when use is being considered during lactation.

Q: How quickly does Xopenex typically start working after inhalation?

A: Studies indicate that the effect of Xopenex begins rapidly. The onset of effect is typically measured as a change in lung function that occurs within approximately 5.5 to 10.2 minutes for the inhalation aerosol and 10 to 17 minutes for the nebulization solution.

Q: What is the expected duration of the effects of Xopenex?

A: As a Short-Acting Beta-Agonist, Xopenex provides temporary relief. The duration of its effects is typically described in regulatory documents as lasting for 3 to 6 hours for the inhalation aerosol and 5 to 8 hours for the nebulization solution.

Q: Is Xopenex considered a 'rescue' inhaler or a 'controller' medicine?

A: Xopenex is classified as a Short-Acting Beta-Agonist (SABA). This class of medicine is intended as a quick-relief or rescue medication to treat or prevent acute episodes of breathing difficulty, not for daily, long-term asthma control.

Q: Are there any long-term health concerns associated with using Xopenex regularly?

A: Official research evidence provides context largely based on short- to intermediate-term follow-up studies. The long-term effects of using the drug for many months or years are not fully established, and certainty regarding these long-term outcomes is described in official limitations as low.

Q: Can Xopenex affect heart rate or blood pressure?

A: Yes, official labeling indicates that Xopenex may affect the cardiovascular system. Adverse reactions commonly reported include tachycardia (increased heart rate). The drug may also cause elevation in blood pressure and heart rate. Caution is advised for individuals with pre-existing heart conditions.

Q: Does Xopenex lose its strength or expire after a certain time?

A: Official handling rules outline when the products must be discarded. For the Inhalation Solution, unused vials must be discarded 2 weeks after the protective foil pouch is opened. For the Inhalation Aerosol (MDI), the device must be discarded once the dose counter reaches zero.

Q: Is Xopenex a steroid medication?

A: No. Xopenex is categorized as a Short-Acting Beta-Agonist (SABA), which is a type of adrenergic bronchodilator. This pharmacological class is distinct from steroid medications.

Q: Can people with thyroid problems use Xopenex?

A: Official documents state that use requires caution in patients with conditions like hyperthyroidism (overactive thyroid). Caution is noted because the drug's properties as a beta2-agonist may potentially stimulate thyroid activity.

Q: How is Xopenex stored correctly?

A: Both the Inhalation Solution and Aerosol should be stored at controlled room temperature and protected from freezing. Additionally, the Inhalation Solution vials must be protected from light and should be kept in the original foil pouch until needed.

Q: Are there any specific instructions for disposing of the used inhaler or solution?

A: Yes. The HFA canister (inhaler) must not be punctured or disposed of in a fire or incinerator due to fire hazard. Unused inhalation solution should be discarded according to the guidance of a healthcare professional or local waste regulations.

Q: What research themes exist regarding Xopenex and its effect on exercise performance?

A: The official indication for Xopenex is not for preventing exercise-induced asthma. Research has focused on its effect on acute changes in lung function (like FEV1), but preventing exercise symptoms is not an FDA-approved use for this drug.

Q: Are there any specific foods or supplements that should not be taken with Xopenex?

A: Official regulatory labeling for Xopenex explicitly states that it does not document specific interactions with food, alcohol, or herbal products.

Q: Is Xopenex known to cause allergic reactions?

A: Yes. The official labeling documents that hypersensitivity reactions may occur, including severe reactions such as angioedema (swelling) and anaphylaxis. The drug is contraindicated for anyone with a known allergy to any component of the product.

Q: Can Xopenex be used to treat a cough that is not related to asthma?

A: The drug is officially indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. The regulatory documents do not include an indication for treating a cough not associated with these specific conditions.

Q: What is the evidence theme regarding Xopenex use in people with diabetes?

A: Caution is advised in patients with diabetes mellitus because the drug's properties as a beta2-agonist may potentially increase serum glucose levels. This increase could potentially aggravate conditions like ketoacidosis.

Q: Is there any information on Xopenex affecting weight?

A: A change in body weight is not listed as a documented adverse reaction in the official regulatory profile of Xopenex.

Q: What should be done if Xopenex seems less effective than it was before?

A: If the drug seems less effective for symptomatic relief, official labeling states this may be a marker of destabilization of asthma that requires reevaluation of the patient and the treatment regimen.

Q: Why is Xopenex sometimes prescribed instead of levosalbutamol?

A: Xopenex is the pure R-enantiomer of albuterol, which is the component responsible for therapeutic activity. Regulatory documents confirm this distinction, but comparative evidence is mixed regarding a substantial difference in overall long-term clinical outcomes versus racemic albuterol.

Q: Does Xopenex contain sulfites or other known allergens?

A: The official label includes a contraindication for any patient with a known history of allergy to any component of the product. Specific allergens such as sulfites are not listed as ingredients in the current solution or aerosol formulations.

Q: How does the use of Xopenex fit into a broader asthma management plan?

A: Xopenex is designed as a quick-relief medication to address acute symptoms. Official information emphasizes that the use of bronchodilators alone may not be adequate, and early consideration of anti-inflammatory agents is noted in the therapeutic regimen.

Q: What are the documented risks of using more Xopenex than prescribed?

A: Official warnings state the total dose or frequency must not be exceeded. Risks associated with excessive use include a higher potential for significant cardiovascular effects (such as arrhythmias and increased heart rate/blood pressure), seizures, and the possibility of dangerously low potassium levels (hypokalemia).

Q: Can Xopenex be used with a spacer device?

A: The official instructions address the use of the Inhalation Aerosol (MDI) device directly, including priming. The use of a spacer device is not specifically detailed in the official prescribing information for the Inhalation Aerosol.

Q: Do official documents mention any effects of Xopenex on mood?

A: Effects on the nervous system are documented in the adverse reactions profile. These commonly reported effects include nervousness and dizziness, and less frequently, anxiety and migraine.

Q: Why do some people experience muscle cramps after using Xopenex?

A: The official adverse reaction list includes leg cramps as a less common reported effect. Additionally, the drug has the potential to cause hypokalemia (low potassium levels), which is a documented safety element related to muscle function.

Q: Does Xopenex interact with caffeine?

A: Official regulatory labeling does not document specific interactions with food, alcohol, or herbal products. This means there is no official regulatory statement concerning interactions with caffeine or other supplements.

Q: Is Xopenex suitable for use during a sudden, severe breathing episode?

A: Yes. Xopenex is classified as a Short-Acting Beta-Agonist (SABA), and its general purpose is to provide rapid relief from bronchospasm during acute episodes of breathing difficulty, often referred to as a sudden, severe breathing episode.

How should Xopenex be stored and disposed of?

The storage and disposal instructions for Xopenex (levalbuterol) differ between the Inhalation Aerosol and the Inhalation Solution.

Storage Requirements

Formulation	Temperature/Environment	Stability/Container Rules
HFA Aerosol	Store at controlled room temperature (20 C to 25 C). Protect from freezing and temperatures above 120 F.	Keep canister tightly closed and discard when dose counter reaches zero.
Inhalation Solution	Store at room temperature. Protect from light and freezing.	Store vials in the original foil pouch. Discard remaining vials 2 weeks after opening the pouch.